Part of our ongoing commitment to helping people with rare bleeding disorders—we have pursued additional trials with Eptacog Beta with the goal of gaining approval for future treatment indications.
Phase 3 Study of the Safety and Efficacy of Coagulation Factor VIIa (Recombinant) for the Prevention of Excessive Bleeding in Patients |
|||
Official Title: Phase 3 Study of the Safety and Efficacy of Coagulation Factor VIIa (Recombinant) for the Prevention of Excessive Bleeding in Patients With Congenital Hemophilia A or B With Inhibitors to Factor VIII or IX Undergoing Elective Major Surgical Procedures SCOPE HIM (SCOPE HIM) Condition/disease: Hemophilia A or B with inhibitors Study Phase: Phase 3 Brief Summary: This is an interventional, prospective, international, multicenter, single-arm, Phase 3, and sequential efficacy and safety study in adolescents and adults with congenital hemophilia A or B with inhibitors to factor VIII (FVIII) or factor IX (FIX) undergoing elective major surgical procedures. Interventions: Drug: LR769 NCT Number: 05695391 |
U.S. Locations: These are the locations in the US participating in the SCOPE HIM clinical trial. Contact information is available for each US location at www.clinicaltrials.gov.
|
Patient Eligibility Criteria |
Status: In Recruitment phase First posted: 6/7/2024 |
Sign up to learn more about our focus on the rare bleeding disorder community